BR112017012588B8 - Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico - Google Patents
Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoicoInfo
- Publication number
- BR112017012588B8 BR112017012588B8 BR112017012588A BR112017012588A BR112017012588B8 BR 112017012588 B8 BR112017012588 B8 BR 112017012588B8 BR 112017012588 A BR112017012588 A BR 112017012588A BR 112017012588 A BR112017012588 A BR 112017012588A BR 112017012588 B8 BR112017012588 B8 BR 112017012588B8
- Authority
- BR
- Brazil
- Prior art keywords
- neurite outgrowth
- compounds
- methods
- heteroaryl
- neurite
- Prior art date
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title abstract 6
- 230000014511 neuron projection development Effects 0.000 title abstract 5
- 239000005711 Benzoic acid Substances 0.000 title abstract 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 title abstract 3
- 235000010233 benzoic acid Nutrition 0.000 title abstract 3
- 125000002619 bicyclic group Chemical group 0.000 title abstract 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 title abstract 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 title abstract 2
- 210000002241 neurite Anatomy 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 229930002330 retinoic acid Natural products 0.000 title abstract 2
- 229960001727 tretinoin Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 2
- 230000003213 activating effect Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- -1 their uses Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010037742 Rabies Diseases 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 231100000878 neurological injury Toxicity 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta). a presente invenção refere-se em geral ao campo dos compostos terapêuticos e, mais especificamente, a certos compostos heteroaril-heteroarila bicíclicos de ácido benzoico da fórmula seguinte (por conveniência, aqui referidos como "compostos bhba"), os quais, inter alia, são agonistas (seletivos) de receptores beta do ácido retinoico (rarbeta) (p. ex., rarbeta2). a presente invenção também diz respeito a composições farmacêuticas que compreendem tais compostos e ao uso de tais compostos e composições, in vitro e in vivo, para ativar (seletivamente) rarbeta (p. ex., rarbeta2), causar ou promover o desenvolvimento de neuritos, causar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e no tratamento de doenças e condições que são mediadas por rarbeta (p. ex., rarbeta2), que melhoram com a ativação de rarbeta (p. ex., rarbeta2), etc., incluindo, p. ex., lesões neurológicas como lesões na medula espinhal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422472 | 2014-12-17 | ||
| GB1422472.9 | 2014-12-17 | ||
| PCT/EP2015/080029 WO2016097004A1 (en) | 2014-12-17 | 2015-12-16 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112017012588A2 BR112017012588A2 (pt) | 2018-11-13 |
| BR112017012588B1 BR112017012588B1 (pt) | 2023-11-07 |
| BR112017012588B8 true BR112017012588B8 (pt) | 2024-03-05 |
Family
ID=55027725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017012588A BR112017012588B8 (pt) | 2014-12-17 | 2015-12-16 | Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9994559B2 (pt) |
| EP (1) | EP3233842A1 (pt) |
| JP (1) | JP6596090B2 (pt) |
| KR (1) | KR102526625B1 (pt) |
| CN (1) | CN107207488B (pt) |
| AU (1) | AU2015367531B2 (pt) |
| BR (1) | BR112017012588B8 (pt) |
| CA (1) | CA2970574C (pt) |
| IL (1) | IL252882B (pt) |
| WO (1) | WO2016097004A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015367531B2 (en) | 2014-12-17 | 2020-04-30 | King's College London | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists |
| GB201610867D0 (en) * | 2016-06-22 | 2016-08-03 | King's College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| CN111892591A (zh) * | 2019-05-06 | 2020-11-06 | 南京科技职业学院 | 一种维奈托克关键中间体的合成方法 |
| GB201907647D0 (en) | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| CN115427401A (zh) * | 2020-05-29 | 2022-12-02 | 巴斯夫欧洲公司 | 取代4-(n′-羟基甲脒基)苯甲酸的制备 |
| CN112552252B (zh) * | 2020-09-30 | 2024-01-02 | 浙江美诺华药物化学有限公司 | 一种氟雷拉纳中间体的制备方法 |
| CN113264832A (zh) * | 2021-05-13 | 2021-08-17 | 南京爱可德夫科技开发有限公司 | 一种合成高纯度2-氟-4-溴苯甲酸叔丁酯的方法 |
| CN116640071A (zh) * | 2023-05-04 | 2023-08-25 | 四川青木制药有限公司 | 一种制备2-甲基4-甲醛肟基苯甲酸及其酯类衍生物的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ309151A (en) | 1995-06-07 | 2000-01-28 | Nippon Shinyaku Co Ltd | a 3-substituted cyano or carbamoyl pyrrole derivative and pharmaceutical composition |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| US6121309A (en) | 1996-03-18 | 2000-09-19 | Eisai Co., Ltd. | Fused-ring carboxylic acid derivatives |
| JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
| GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
| CA2307613A1 (en) * | 1997-10-22 | 1999-04-29 | Eisai Co., Ltd. | Retinoic acid agonist as a prophylactic and therapeutic agent for nephritis |
| JP2000154150A (ja) * | 1997-10-22 | 2000-06-06 | Eisai Co Ltd | 腎炎予防・治療剤としてのレチノイン酸アゴニスト |
| BR0012327A (pt) * | 1999-07-09 | 2002-07-02 | Ortho Mcneil Pharm Inc | Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados |
| US20020048580A1 (en) * | 2000-06-07 | 2002-04-25 | Institut National De La Sante Et De La Recherche Medicale | Method of inducing lung branching |
| US7041685B2 (en) | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| WO2003062230A1 (en) * | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
| JP4637578B2 (ja) | 2002-08-09 | 2011-02-23 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体−５の調節因子としての１，２，４−オキサジアゾール類 |
| ES2624610T3 (es) | 2003-04-11 | 2017-07-17 | Ptc Therapeutics, Inc. | Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| EP1815206B1 (en) * | 2004-10-13 | 2016-04-06 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| EP1907347A2 (en) | 2005-07-12 | 2008-04-09 | Arcadia Pharmaceuticals Inc. | Compounds with activity at retinoic acid receptors |
| RU2010154473A (ru) | 2008-05-30 | 2012-07-10 | Фостер Вилер Энергия Ой (Fi) | Способ и устройство для генерации мощности сжиганием обогащенного кислородом топлива |
| KR101220182B1 (ko) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| GB0915196D0 (en) * | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| US20120289476A1 (en) | 2009-12-11 | 2012-11-15 | Jay Allan Barth | Methods for treating methylmalonic acidemia |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2015367531B2 (en) * | 2014-12-17 | 2020-04-30 | King's College London | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists |
-
2015
- 2015-12-16 AU AU2015367531A patent/AU2015367531B2/en active Active
- 2015-12-16 WO PCT/EP2015/080029 patent/WO2016097004A1/en active Application Filing
- 2015-12-16 CN CN201580073462.9A patent/CN107207488B/zh active Active
- 2015-12-16 EP EP15817206.4A patent/EP3233842A1/en active Pending
- 2015-12-16 CA CA2970574A patent/CA2970574C/en active Active
- 2015-12-16 US US15/533,492 patent/US9994559B2/en active Active
- 2015-12-16 KR KR1020177019558A patent/KR102526625B1/ko active IP Right Grant
- 2015-12-16 JP JP2017532660A patent/JP6596090B2/ja active Active
- 2015-12-16 BR BR112017012588A patent/BR112017012588B8/pt active IP Right Grant
-
2017
- 2017-06-13 IL IL252882A patent/IL252882B/en active IP Right Grant
-
2018
- 2018-06-05 US US15/997,796 patent/US10385044B2/en active Active
-
2019
- 2019-08-09 US US16/536,441 patent/US10752616B2/en active Active
-
2020
- 2020-08-19 US US16/997,855 patent/US11401265B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102526625B1 (ko) | 2023-04-27 |
| US20170327489A1 (en) | 2017-11-16 |
| CN107207488A (zh) | 2017-09-26 |
| EP3233842A1 (en) | 2017-10-25 |
| BR112017012588B1 (pt) | 2023-11-07 |
| IL252882B (en) | 2020-04-30 |
| US20190010146A1 (en) | 2019-01-10 |
| AU2015367531A1 (en) | 2017-07-06 |
| AU2015367531B2 (en) | 2020-04-30 |
| KR20170097125A (ko) | 2017-08-25 |
| CN107207488B (zh) | 2020-11-17 |
| JP6596090B2 (ja) | 2019-10-23 |
| JP2017537967A (ja) | 2017-12-21 |
| US11401265B2 (en) | 2022-08-02 |
| CA2970574A1 (en) | 2016-06-23 |
| US10385044B2 (en) | 2019-08-20 |
| BR112017012588A2 (pt) | 2018-11-13 |
| US10752616B2 (en) | 2020-08-25 |
| IL252882A0 (en) | 2017-08-31 |
| WO2016097004A1 (en) | 2016-06-23 |
| US20210130337A1 (en) | 2021-05-06 |
| CA2970574C (en) | 2023-09-19 |
| US20200131165A1 (en) | 2020-04-30 |
| US9994559B2 (en) | 2018-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017012588B8 (pt) | Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| BR112019024747A2 (pt) | formulações de dose fixa | |
| BR112015011158A2 (pt) | triazolopirazina | |
| BR112014018475A8 (pt) | Compostos de imidazopirrolidinona, suas formas cristalinas e seu uso, e composição farmacêutica | |
| BR112014022000A2 (pt) | compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende | |
| CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
| BR112014031731A2 (pt) | entidades químicas, composições farmacêuticas, usos de entidades químicas ou de composições, compostos ou sais farmaceuticamente aceitáveis dos mesmos e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática pde1 e para modular a atividade da enzima pde1 | |
| BR112016022553A2 (pt) | Compostos e métodos para entrega transmembrana de moléculas? | |
| BR112015010360A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que pode se ligar especificamente ao sítio ii de uma il-6 humana, seus usos, ácido nucleico, composição, vetor, célula, e processo para produzir a mesma | |
| CO7310531A2 (es) | 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos | |
| BR112014026703A2 (pt) | inibidores de dna-pk | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112015006029A2 (pt) | compostos aza bicíclicos como agonistas de receptor m1 muscarínicos | |
| CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
| BR112014012056A8 (pt) | compostos farmacêuticos | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112014019357A8 (pt) | Derivados de tetra-hidro- quinazolinona como inibidores de tanc e parp | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
| BR112014011333A2 (pt) | derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares | |
| CO7111276A2 (es) | Compuestos de 3,5 disustituido-3h imidazo[4,5-b] piridina y 3,5 disustituido - 3h-[1,2,3] triaolo [4,5-b] piridina novedosos como moduladores d proteínas cinasas c-met | |
| BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/12/2015, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2757 DE 07/11/2023, QUANTO AO ITEM (54) TITULO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2771 DE 15/02/2024, QUANTO AO ITEM (54) TITULO. |